The power of simplicity
- 1 October 2003
- journal article
- review article
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 14 (1_suppl) , 15-19
- https://doi.org/10.1258/095646203322491833
Abstract
Many years of use have confirmed didanosine to be among the most potent of nucleoside analogues. Didanosine's potency has been demonstrated in mono-, dual- and trip le-therapy. Didanosine is currently available as a once-daily, enteric-coated tablet, which has reduced gastrointestinal side effects compared with the older, buffered formulation. Once-daily dosing and good tolerability improve adherence, and hence also virological control. The prevalence of phenotypic nucleoside resistance to didanosine is low compared with that to zidovudine, lamivudine and abacavir. At least 6 nucleoside analogue mutations are needed in order for the virus to lose sensitivity to didanosine. Didanosine is effective in patients failing lamivudine therapy who have the M184V mutation. Enteric-coated didanosine is also an important component of early therapy, due to its potency and ease of administration.Keywords
This publication has 10 references indexed in Scilit:
- Virological and Immunological Responses to a Once-a-Day Antiretroviral Regimen with Didanosine, Lamivudine and EfavirenzAntiviral Therapy, 2002
- Tolerability of Enteric-Coated Didanosine Capsules Compared With Didanosine Tablets in Adults With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapyHIV Medicine, 2001
- Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugsAIDS, 2001
- A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)*AIDS, 2000
- Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyureaAIDS, 2000
- Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trialAIDS, 1999
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992